Navigation Links
RAPAFLO(TM) (silodosin) Provides Rapid and Sustained Benign Prostatic Hyperplasia (BPH) Symptom Relief in as Little as Three Days
Date:5/8/2009

and 1.5%, respectively). In addition, the incidence of treatment-related dizziness was only slightly higher among RAPAFLO(TM)- than placebo-treated patients (3.2% vs. 1.1%).

About RAPAFLO(TM)

RAPAFLO(TM) is an effective, uniquely selective alpha-1 adrenergic receptor antagonist. RAPAFLO(TM) maximizes target organ activity by binding with high affinity to the alpha (1A) receptors concentrated in the prostate. The antagonism of these receptors cause the smooth muscles in these tissues to relax and results in improved urine flow and a reduction in BPH symptoms. The binding affinity for the alpha (1B) receptors that cause smooth muscle in peripheral vessels is significantly lower, which may minimize orthostatic hypotension.

The most common drug-related side effect was retrograde ejaculation. The second most commonly-reported adverse event was dizziness. The incidence of treatment-related dizziness was low and only slightly higher among RAPAFLO(TM) than placebo-treated patients (11 vs. 3 patients).

Previously presented data included information that in clinical trials RAPAFLO(TM) was administered with a single dose of medications for erectile dysfunction in healthy male subjects (N=24) and that there were no reported events of symptomatic orthostasis or dizziness. RAPAFLO(TM) demonstrated no meaningful electro cardiac effects during Phase 3 trials and during thorough QTc testing as required for new chemical entities by the FDA.

RAPAFLO(TM) was originally developed by Kissei Pharmaceutical Co., Ltd. in Japan, where RAPAFLO(TM) is the BPH market leader, and licensed to Watson for the U.S., Canada and Mexico markets.

About Watson Pharmaceuticals, Inc.

Watson Pharmaceuticals, Inc. (NYSE: WPI) is a global leader in the development and distribution of pharmaceuticals wi
'/>"/>

SOURCE Watson Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related medicine technology :

1. Watson Announces United States Availability of RAPAFLO(TM) (silodosin), a Novel New Treatment in Benign Prostatic Hyperplasia (BPH)
2. BioCryst Provides Peramivir Update and Reports First Quarter 2009 Financial Results
3. Poniard Pharmaceuticals Reports First Quarter 2009 Financial Results and Provides a Corporate Update
4. USAID Provides $5M in Emergency Support as Swine Flu Spreads
5. Lexicon Pharmaceuticals Provides Clinical Pipeline Update and Reports 2009 First Quarter Results
6. Strativa Pharmaceuticals Provides Product Pipeline Update
7. Poniard Pharmaceuticals Reports Fourth Quarter and Year End 2008 Financial Results and Provides a Corporate Update
8. VirtualScopics Quantitative Imaging Provides Primary Endpoint in Cartilage Repair Pivotal Clinical Trial
9. Savient Provides Update on Pegloticase BLA
10. USAID Provides Malaria Assistance to Zimbabwe
11. Synvista Therapeutics Announces Termination of Clinical Trials of Alagebrium and SYI-2074 and Provides Business Update
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/14/2009)... 14 According to Millennium Research Group ... intelligence, increased use of safety devices for small-bore ... a key driver of the enteral feeding device ... new US and European Markets for Enteral ... giving set segment will experience the greatest impact ...
(Date:12/14/2009)... -- Caliper Life Sciences, Inc. (Nasdaq: ... and services for drug discovery and life sciences ... sale of Xenogen Biosciences Corporation ("XenBio"), a subsidiary ... Farms, Inc. for approximately $11 million. XenBio ... acquisition of Xenogen Corporation in 2006. Caliper ...
(Date:12/14/2009)... The U.S. Food and Drug Administration (FDA) ... Suspension for the treatment of schizophrenia in adults, ... ) announced today. ZYPREXA RELPREVV, a long-acting intramuscular ... to four weeks. ,, Different from both oral ... allow for stable concentrations of the active drug ...
Breaking Medicine Technology:Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 2Enteral Feeding Device Market To Generate More Than $700 Million in the US & Europe by 2014 3Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 2Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 3Caliper Completes Strategic Sale of Small Animal Services Subsidiary to Taconic 4FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 2FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 3FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 4FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 5FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 6FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 7FDA Approves Lilly's ZYPREXA(R) RELPREVV(TM) for Treatment of Schizophrenia in Adults 8Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 55775 1Endo Pharmaceuticals to Present at Thomas Weisel Partners Healthcare Conference 2009 55775 2In Case You Missed It Senator Bob Dole in The Washington Post 3A Starting Over on Health Care 55770 1In Case You Missed It Senator Bob Dole in The Washington Post 3A Starting Over on Health Care 55770 2Prostate Cancer Over Diagnosed 3A Study 55767 1Prostate Cancer Over Diagnosed 3A Study 55767 2Prostate Cancer Over Diagnosed 3A Study 55767 3
... March 7 NovaBay Pharmaceuticals, Inc. (NYSE ... first-in-class, novel, synthetic anti-infective products for the ... of bacterial, fungal, and viral infections without ... showing that NVC-422, the Company,s lead Aganocide(R) ...
... Poster Session at the 67th Annual Meeting of the ... Galderma Laboratories, L.P. today announced interim findings from a ... (R) (clobetasol propionate) Spray 0.05% followed by treatment ... an interim analysis of the data are to be ...
Other Medicine Technology:NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection 2NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection 3NovaBay Pharmaceuticals Announces Lead Anti-infective Product Candidate, NVC-422, Shown to be Effective in Treating Topical Fungal Infection 4Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis 2Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis 3Galderma Announces Interim Data Relating to Sequential Treatment Regimen of Clobex(R) Spray Followed by Vectical(TM) Ointment in Managing Plaque Psoriasis 4
(Date:12/14/2009)... 15 In today,s academic medical centers, ... ever. Now the University HealthSystem Consortium (UHC) has ... Analysis: Achieving Cost Efficiencies in Health Care, ... environments. These new materials, developed with the input ... a practical guide to planning, implementing, and managing ...
(Date:12/14/2009)... Ill. and HOLLYWOOD, Fla., Dec. 14 /PRNewswire-FirstCall/ ... announced today a definitive agreement to acquire ... a leading provider of laboratory information management ... ,, The acquisition strengthens Abbott,s competitive ... advanced web-based applications to help laboratories efficiently ...
(Date:12/14/2009)... Aflac Incorporated announced today that it ... senior notes with a coupon of 6.9%. The ... 98.951 to yield 6.984%. The company anticipates using ... and general corporate purposes. ,, Commenting on the ... and Chief Financial Officer Kriss Cloninger III commented: ...
(Date:12/14/2009)... Twelve variants seen in one gene, researchers say , , ... pinpointed a dozen genetic variants in a single gene ... University School of Medicine in St. Louis analyzed the ... heart failure, and identified 129 variants in four genes ... of 1,117 whites with heart failure and 625 healthy ...
(Date:12/14/2009)... doses from common CT procedures vary widely and are higher than ... a new study led by University of California, San Francisco ... ... (Vocus) December 14, 2009 -- Radiation doses from common CT procedures ... increased risk for cancer, according to a new study led by ...
Breaking Medicine News(10 mins):Health News:University HealthSystem Consortium Offers Value Analysis Professionals Insightful New Resources 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 2Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 3Health News:Abbott to Acquire STARLIMS Technologies Ltd., a Leader in Laboratory Information Management Systems 4Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 2Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 3Health News:Aflac Incorporated Prices $400 Million of 30-Year Senior Notes 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 2Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 3Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 4Health News:Variable Doses of Radiation Raise Safety Concerns for CT Procedures 5
... hospitals associated with Fox Chase Cancer Center in ... academic cancer center, where most new treatment protocols ... is provided, is a highly effective model for ... , Fox Chase, an NCI-designated Comprehensive ...
... - Celecoxib, the anti-inflammatory medication also known by the ... reduces a specific proliferation measurement of precancerous lesions in ... of Texas M. D. Anderson Cancer Center. This finding ... cancer in individuals at higher risk of developing the ...
... 15 JumpStart Inc., the Northeast Ohio,venture ... innovative,early-stage businesses and ideas, has announced an ... Cleveland-based company is,commercializing a patented, Federal Drug ... easily measure cervical length in,pregnant women, which ...
... focus of 48 NQF-endorsed measures, WASHINGTON, May ... hurdle in the United States, the National Quality,Forum ... on,measuring the performance of acute care hospitals, including ... care,of venous thromboembolism., "It has been difficult ...
... does not appear to help quality of life for ... (HealthDay News) -- Adding chemotherapy to other treatments being ... linked to asbestos exposure, does not appear to improve ... mesothelioma (MPM), which is usually fatal, is a cancer ...
... AARP commends Governor Paterson,s leadership in proposing prescription,drug ... 15 AARP strongly believes,New York has a ... proposals which address the undue influence that,pharmaceutical companies ... pocket books but the treatment they receive., ...
Other Medicine News:Health News:Partnership of academic centers and community hospitals effective model for disseminating advances 2Health News:Partnership of academic centers and community hospitals effective model for disseminating advances 3Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 2Health News:Celebrex shows benefit in first-of-its-kind lung cancer chemoprevention trial 3Health News:CerviLenz Receives JumpStart Investment 2Health News:CerviLenz Receives JumpStart Investment 3Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 2Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 3Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 4Health News:National Quality Forum Endorses Consensus Standards for Quality of Hospital Care 5Health News:Chemo for Mesothelioma Offers Limited Survival Benefits 2Health News:AARP Statement on Governor's Bill for Prescription Drug Marketing Reform and Transparency 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: